Clinical Trials
Closed
Phase
Accrual
95%
SWOG Clinical Trial Number
S0635
A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma with BAC Features
Research Committee(s)
Lung Cancer
Activated
07-15-2007
Closed
08-15-2011
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S0636
A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Never-Smokers with Stage IIIB and IV Primary NSCLC Adenocarcinomas
Research Committee(s)
Lung Cancer
Activated
07-15-2007
Closed
09-01-2010
Closed
Phase
Accrual
11%
Published
SWOG Clinical Trial Number
S0600
Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) or Bevacizumab (NSC-704865) as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with either FOLFOX, OPTIMOX, or XELOX
Research Committee(s)
Gastrointestinal Cancer
Activated
06-15-2007
Closed
11-10-2010
ClinicalTrials.gov Registry Number
NCT00499369
Closed
Phase
Accrual
19%
Published
SWOG Clinical Trial Number
S0521
A Randomized Trial of Maintenance versus Observation for Patients with Previously Untreated Low and Intermediate Risk Acute Promyelocytic Leukemia (APL), Phase III
Research Committee(s)
Leukemia
Activated
06-01-2007
ClinicalTrials.gov Registry Number
NCT00492856
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0354
A Phase II Study of CNTO 328, A Monoclonal Antibody Against Interleukin-6 (IL-6) in Patients with Hormone Refractory Prostate Cancer
Research Committee(s)
Genitourinary Cancer
Activated
04-01-2007
Closed
05-15-2008
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0622
Phase II Studies of Two Different Schedules of Dasatinib (NSC-732517) in Bone-Metastasis Predominant Metastatic Breast Cancer
Research Committee(s)
Breast Cancer
Activated
03-15-2007
Closed
12-15-2010
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0353
Phase II Study of Intravesical Gemcitabine in Patients with Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG
Research Committee(s)
Genitourinary Cancer
Activated
11-15-2006
Closed
10-15-2009
Closed
Phase
Accrual
0%
SWOG Clinical Trial Number
S0408
A Phase II Trial of Neoadjuvant Capecitabine, Oxaliplatin and Bevacizumab for Resectable Colorectal Metastases in the Liver
Research Committee(s)
Gastrointestinal Cancer
Activated
11-15-2006
Closed
04-01-2007
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0530
A Phase II Trial of Cytarabine and Clofarabine in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Research Committee(s)
Leukemia
Activated
10-01-2006
Closed
08-01-2008
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0500
A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients who Have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment
Research Committee(s)
Breast Cancer
Activated
10-01-2006
Closed
03-15-2012
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0528
Phase I Study Evaluating the Combination of Lapatinib (GW572016; NSC-727989; IND-75,093) and Everolimus (RAD001; NSC-733504; IND-75,093) in Patients with Advanced Solid Tumors
Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
09-01-2006
Closed
08-25-2009
ClinicalTrials.gov Registry Number
NCT00352443
Closed
Phase
Accrual
99%
Published
SWOG Clinical Trial Number
S0421
Phase III Study of Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer
Research Committee(s)
Genitourinary Cancer
Activated
08-21-2006
Closed
05-01-2010
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0601
A Phase II Study of Combination Rituximab-CHOP and Bortezomib (Velcade) (R-CHOP-V) Induction Therapy Followed by Bortezomib Maintenance (VM) Therapy for Patients With Newly Diagnosed Mantle Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
08-15-2006
Closed
06-01-2008
Closed
Phase
Accrual
0%
SWOG Clinical Trial Number
S0506
Phase II Trial of PS-341 (Bortezomib, NSC-681239) Followed by the Addition of Gemcitabine at Progression in Recurrent or Metastatic Nasopharyngeal Carcinoma
Research Committee(s)
Head and Neck Cancer
Activated
08-15-2006
Closed
01-10-2007
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0536
A Phase II Trial of Combination Carboplatin, Paclitaxel, Cetuximab and Bevacizumab (NSC-704865) Followed by Cetuximab and Bevacizumab in Patients with Advanced Non-Small Cell Lung Cancer
Research Committee(s)
Lung Cancer
Activated
08-15-2006
Closed
09-15-2007
Closed
Phase
Accrual
25%
Published
SWOG Clinical Trial Number
S0526
Phase II Trial of Pemetrexed in Patients with Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC)
Research Committee(s)
Lung Cancer
Activated
07-01-2006
Closed
10-01-2008
Closed
Phase
Accrual
91%
Published
SWOG Clinical Trial Number
S0605
A Phase II Study of Lenalidomide (Revlimid®) (NSC-703813) for Previously Untreated Non-M3, Deletion 5q Acute Myeloid Leukemia (AML) in Patients Age 60 or Older Who Decline Remission Induction Chemotherapy
Research Committee(s)
Leukemia
Activated
06-15-2006
Closed
07-01-2010
Closed
Phase
Accrual
16%
Published
SWOG Clinical Trial Number
S0533
A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients with Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer
Research Committee(s)
Lung Cancer
Activated
06-15-2006
Closed
03-01-2010
Closed
Phase
Accrual
0%
SWOG Clinical Trial Number
S0308
A Phase III Randomized, Multicentered Non-Inferiority Trial Evaluating the Efficacy of Oral Ibandronate versus Intravenous Zoledronate in the Reduction of Skeletal-Related Events in Patients with Metastatic Breast Cancer
Research Committee(s)
Breast Cancer
Activated
05-15-2006
Closed
06-08-2006
Closed
Phase
Accrual
9%
SWOG Clinical Trial Number
S0425
Neoadjuvant Chemoradiation Therapy with Oxaliplatin and Capecitabine for Patients with Surgically Resectable Gastric Cancer: A Pilot Phase II Trial with Molecular Correlates
Research Committee(s)
Gastrointestinal Cancer
Activated
05-01-2006
Closed
01-15-2008